H.C. Wainwright raised the firm’s price target on Capricor Therapeutics to $77 from $40 and keeps a Buy rating on the shares. The firm says deramiocel’s capacity to treat Duchenne muscular dystrophy -cardiomyopathy becomes the focus of current rolling application submission. The firm sees “exciting times with strong science and data foundation” for Capricor.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- DOJ may push for breakup of Google: Morning Buzz
- Capricor Advances Duchenne Treatment with FDA Submission
- Capricor announces initiation of rolling submission of BLA for deramiocel
- Capricor Therapeutics call volume above normal and directionally bullish
- Biotech Alert: Searches spiking for these stocks today